Nicolet Advisory Services LLC Sells 991 Shares of Humana Inc. (NYSE:HUM)

Nicolet Advisory Services LLC lessened its stake in shares of Humana Inc. (NYSE:HUM) by 46.6% during the third quarter, Holdings Channel.com reports. The firm owned 1,137 shares of the insurance provider’s stock after selling 991 shares during the period. Nicolet Advisory Services LLC’s holdings in Humana were worth $360,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in HUM. Mendota Financial Group LLC boosted its holdings in Humana by 9.2% in the second quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock worth $119,000 after acquiring an additional 27 shares in the last quarter. Capital Advisors Ltd. LLC lifted its position in Humana by 17.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock valued at $80,000 after acquiring an additional 31 shares in the last quarter. CarsonAllaria Wealth Management Ltd. boosted its stake in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. Moors & Cabot Inc. increased its holdings in Humana by 2.5% during the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after purchasing an additional 40 shares in the last quarter. Finally, Harbour Investments Inc. raised its stake in shares of Humana by 10.5% in the second quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock worth $161,000 after purchasing an additional 41 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Trading Up 0.8 %

Shares of HUM stock opened at $298.11 on Friday. The stock has a market capitalization of $35.90 billion, a price-to-earnings ratio of 26.40, a PEG ratio of 2.33 and a beta of 0.52. The company’s fifty day simple moving average is $276.83 and its two-hundred day simple moving average is $330.68. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $527.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. As a group, analysts anticipate that Humana Inc. will post 15.86 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.19%. Humana’s dividend payout ratio (DPR) is currently 31.36%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price on the stock in a research report on Tuesday, October 8th. Royal Bank of Canada reduced their target price on shares of Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Wells Fargo & Company dropped their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. boosted their target price on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 21st. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Humana currently has a consensus rating of “Hold” and an average target price of $315.86.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.